Retatrutide
Phase 3 obesity data positive; BLA submission planned for Q1 2027.
What it is
A triple GIP, GLP-1 and glucagon receptor agonist injection in late-stage development for obesity and related conditions. Lilly says the clinical data package for obesity is now complete.↗ source
Why it matters to the stock. Retatrutide is the next incretin leg of Lilly's obesity strategy and the biggest pipeline catalyst after Foundayo; its filing timing and efficacy versus Zepbound will drive the medium-term outlook.
News
Retatrutide TRIUMPH-2 detail: 20.8% weight loss at 12 mg, published in The Lancet
Lilly presented detailed TRIUMPH-2 results for retatrutide at the EASD meeting in Milan on September 29, 2026, with a simultaneous Lancet publication.
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Lilly's Q2 2026 revenue rose 48%; revenue guidance raised to $85B-$87B
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48%, with Mounjaro up 91% and Zepbound up 46%.
Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 positive; up to 22.6% weight loss
Lilly reported positive topline results from two Phase 3 trials of retatrutide, its triple GIP, GLP-1 and glucagon agonist.
Retatrutide meets primary endpoints in TRIUMPH-2 and TRIUMPH-3
Lilly reported that retatrutide met the primary endpoint in two more Phase 3 obesity trials: TRIUMPH-2 in adults with obesity and type 2 diabetes, and TRIUMPH-3 in adults with severe obesity and cardiovascular disease.
Retatrutide hits 25% weight loss at 80 weeks in TRIUMPH-1 Phase 3
Lilly reported topline results from TRIUMPH-1, a Phase 3 obesity trial of retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist.